IGM Biosciences Inc. is a biotechnology company. It engages in the research and development of engineered Immunoglobulin M antibodies for the treatment of cancer patients. The company's lead product candidate is IGM-2323, a bispecific T cell engaging IgM, which are in clinical stage. IGM Biosciences Inc. is based in Mountain View, California.
| Revenue (Most Recent Fiscal Year) | $2.68M |
| Net Income (Most Recent Fiscal Year) | $-195.79M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 29.65 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 113.90 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -7417.79% |
| Net Margin (Trailing 12 Months) | -7417.79% |
| Return on Equity (Trailing 12 Months) | -317.97% |
| Return on Assets (Trailing 12 Months) | -71.43% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.71 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.71 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.01 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.86 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.24 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.27 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 59.78M |
| Free Float | 25.70M |
| Market Capitalization | $79.50M |
| Average Volume (Last 20 Days) | 0.16M |
| Beta (Past 60 Months) | 0.61 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 57.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 42.79% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |